Recent in vivo studies in mice showed that lovastatin can overcome gefitinib resistance in NSCLC cells harbouring a K-Ras mutation via inhibition of the MAPK and PI3K/AKT pathways55. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.